2Duensing A, Heinrich MC, Fletcher CD, et al. Biology of gastrointestinal stromal tumors:KIT mutations and beyond[J]. Cancer Invest, 2004,22(1):106-116.
3Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors[J]. Science, 2003, 299((5607) :708-710.
4Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors[J]. Gastroenterology,200325(3):660-667.
5Mechtersheimer G, Egerer G, Hensel M, et al. Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib[J]. Virchows Arch,2004,444(2):108-118.
6Joensuu H, Roberts PJ, Sarlomo-Rikala M,et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor[J]. N Engl J Med,2001,344(14):1 052-1 056.
7Van Oosterom AT, Judson I, Verwej J,et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumouts: a phase I study[J], Lancet,2001,358(9291):1 421-1 423.
8Van Oosterom AT, Judson IR, Verwej J,et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group[J]. Eur J Cancer,2002,38( 5 ) :83-87.
9Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors[J]. N Engl J Med 2002,347(7):472-480.
10Dagher R,Cohen M,Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors[J]. Clin Cancer Res, 2002, 8(10):3 034-3 038.
